Synovial Tissue Response to Treatment in Psoriatic Arthritis

Veronica Codullo1, 2, Iain B McInnes*, 1
1 University of Glasgow, UK
2 University of Pavia, Italy

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 2331
Abstract HTML Views: 1541
PDF Downloads: 465
Total Views/Downloads: 4342
Unique Statistics:

Full-Text HTML Views: 969
Abstract HTML Views: 790
PDF Downloads: 339
Total Views/Downloads: 2103

Creative Commons License
© Codullo and McInnes; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Glasgow Biomedical Research Centre, University of Glasgow, 120 University Place, Glasgow, G12 8QQ, UK; Tel: +44 141 330 8412; Fax: +44 141 337 3217; E-mail:


Following its validation and wide application in rheumatoid arthritis (RA), synovial tissue analysis has recently been applied to studies on Psoriatic Arthritis (PsA). Such studies aim to thereby clarify its distinctive features and the nature of specific responses upon administration of disease modifying anti-rheumatic drug (DMARD) or biologic agents. In consequence, insights to disease pathogenesis, drugs’ mechanisms of action (MOA) and biomarkers of response have emerged. Data from pilot and open-label studies, and recently from randomized controlled trials, have helped in refining the therapeutic approaches to PsA patients, by improving understanding of MOA and in provision of biomarkers of response. The availability of less invasive and reproducible analysis techniques to obtain and evaluate synovial biopsies will further enhance the utility of this approach in due course.

Keywords: Biologic therapy, psoriatic arthritis, biomarker, synovial tissue,.